InvestorsObserver
×
News Home

Is Odonate Therapeutics Inc (ODT) a Bad Choice in Biotechnology Monday?

Monday, April 12, 2021 11:34 AM | InvestorsObserver Analysts

Mentioned in this article

Is Odonate Therapeutics Inc (ODT) a Bad Choice in Biotechnology Monday?

The 11 rating InvestorsObserver gives to Odonate Therapeutics Inc (ODT) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 8 percent of stocks in the Biotechnology industry, ODT’s 11 overall rating means the stock scores better than 11 percent of all stocks.

Overall Score - 11
ODT has an Overall Score of 11. Find out what this means to you and get the rest of the rankings on ODT!

What do These Ratings Mean?

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 11 would rank higher than 11 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Odonate Therapeutics Inc Stock Today?

Odonate Therapeutics Inc (ODT) stock is trading at $3.51 as of 11:30 AM on Monday, Apr 12, a loss of -$0.34, or -8.83% from the previous closing price of $3.85. The stock has traded between $3.45 and $3.85 so far today. Volume today is low. So far 2,034,658 shares have traded compared to average volume of 8,080,941 shares.

Click Here to get the full Stock Score Report on Odonate Therapeutics Inc (ODT) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App